AOD-9604 Pre-Surgery Hold Window: Clinical Guidance for Patients and Prescribers

What Is AOD-9604 and Why Does It Matter Before Surgery?

AOD-9604 is a synthetic peptide corresponding to amino acids 176 through 191 of human growth hormone, with an added tyrosine residue at the N-terminus. Unlike intact GH, it does not bind the classical GH receptor and does not raise IGF-1 [1]. Its primary pharmacological action appears to be stimulation of lipolysis through a beta-3 adrenergic-like mechanism, demonstrated in murine models by Heffernan et al. [1].

Why Surgeons and Anesthesiologists Need to Know

Surgery imposes a profound neuroendocrine stress response. Cortisol, catecholamines, and endogenous GH all spike within the first hour of incision [2]. Any exogenous agent that further shifts lipolytic tone or catecholamine sensitivity could theoretically amplify metabolic instability, change free fatty acid flux into an already stressed myocardium, or alter glucose homeostasis during anesthesia.

The anesthesiologist's pre-op checklist increasingly includes peptides and biologics. A 2022 ASA practice advisory noted that non-approved compounded agents with hormonal or receptor-mediated activity should be disclosed and documented before any general or regional anesthetic [3].

The Fundamental Evidence Gap

No randomized controlled trial has studied AOD-9604 in a peri-operative human population. The key animal lipolysis data come from Heffernan et al. (Endocrinology, 2001), which used obese Zucker rats and C57BL/6J mice treated with subcutaneous AOD-9604 at doses ranging from 250 to 500 mcg/kg [1]. Human Phase II data from Metabolic Pharmaceuticals (2001 to 2004) examined weight loss endpoints but did not assess surgical safety or peri-operative pharmacodynamics [4].

This gap forces prescribers to reason from mechanism, pharmacokinetics, and general peri-operative peptide principles rather than direct clinical evidence.

Pharmacokinetics of AOD-9604: What Drives the Hold Duration

Understanding the hold window requires knowing how quickly AOD-9604 clears. The peptide has an estimated plasma half-life of approximately 30 minutes after subcutaneous injection in rodent models [1]. In humans, no published PK study with a full concentration-time curve exists in peer-reviewed literature.

Half-Life vs. Pharmacodynamic Duration

A short plasma half-life does not mean short pharmacodynamic effect. Beta-3 adrenergic receptor upregulation, changes in adipocyte enzyme expression, and downstream free fatty acid flux can persist well beyond peptide clearance. This distinction matters for surgical planning.

Receptor-level effects on lipolytic enzymes (hormone-sensitive lipase and adipose triglyceride lipase) may remain altered for 48 to 72 hours after the last dose based on analogous beta-adrenergic agonist data [5]. An elevated free fatty acid environment peri-operatively has been associated with increased myocardial oxygen demand in non-cardiac surgery patients [6].

Protein Binding and Anesthetic Interactions

AOD-9604 is a small peptide and is not expected to compete significantly for plasma protein binding sites occupied by common anesthetic agents such as propofol or fentanyl. No pharmacokinetic interaction study has been conducted. Out of an abundance of caution, HealthRX applies the same conservative hold used for other GH-axis peptides.

Why 7 Days Is the HealthRX Threshold

Seven days represents more than 300 estimated half-lives based on a 30-minute PK value. That ensures plasma peptide levels are undetectable. The additional days beyond simple clearance account for receptor-level normalization, return of baseline lipolytic tone, and alignment with the general principle that elective surgery should not be scheduled during any active peptide or hormone titration period [7].

Peri-Operative Risks Specific to Lipolytic Peptides

Lipolytic agents as a class introduce several peri-operative considerations that differ from standard small-molecule drugs.

Free Fatty Acid Flux and Cardiac Stress

Elevated circulating free fatty acids (FFAs) impair mitochondrial function in cardiac and skeletal muscle under conditions of metabolic stress. A prospective cohort of 1,204 non-cardiac surgery patients published in Anesthesiology found that pre-operative FFA levels above 0.8 mmol/L correlated with a statistically significant increase in troponin elevation at 48 hours post-op (P<0.01) [6]. AOD-9604's lipolytic mechanism could theoretically contribute to elevated baseline FFAs if dosing continues close to the surgical date.

Glucose Regulation During General Anesthesia

The GH axis influences insulin sensitivity. Although AOD-9604 does not activate the GH receptor [1], downstream effects on adipokine signaling may modestly affect insulin sensitivity. The American Diabetes Association's Standards of Care in Diabetes 2024 recommend maintaining blood glucose between 140 and 180 mg/dL intra-operatively, and any agent that shifts insulin sensitivity in the days before surgery warrants a washout period [8].

Wound Healing and Anabolic Balance

Growth hormone fragments have been studied for effects on cartilage and connective tissue. A 2009 publication in Osteoarthritis and Cartilage reported that AOD-9604 may have chondroprotective properties at doses of 100 mcg/kg in rats [9]. Whether this translates to improved or altered wound healing in post-surgical humans is unknown. The conservative approach is to allow the surgical wound to begin primary healing under endogenous hormonal control before reintroducing any exogenous GH-axis peptide.

The 7-Day Pre-Surgery Hold: Step-by-Step Protocol

The HealthRX peri-operative hold protocol for AOD-9604 follows a structured sequence designed to minimize peri-operative risk while preserving the patient's treatment continuity.

Step 1: Identify Surgery Date and Calculate Hold Start

Count back 7 full calendar days from the scheduled surgery date. The final AOD-9604 dose is given on day minus 8. Example: surgery on August 15 means the last dose is August 7.

Step 2: Notify the Surgical Team

Patients must disclose AOD-9604 use to both the operating surgeon and the anesthesiologist at the pre-operative appointment. The disclosure should include the dose (commonly 250 to 500 mcg subcutaneously once daily), frequency, and the date of the last dose. The Joint Commission's medication reconciliation standards require documentation of all biologic and peptide agents in the pre-operative record [10].

Step 3: Pre-Op Lab Check

Order a fasting metabolic panel and lipid panel within 14 days of surgery if not done in the prior 30 days. Baseline fasting glucose and FFA values give the anesthesia team a reference point. The ADA's peri-operative glucose targets apply to all surgical patients, not only those with diagnosed diabetes [8].

Step 4: Intra-Operative Glucose Monitoring

For procedures lasting more than 2 hours under general anesthesia, glucose monitoring every 60 minutes is consistent with current guidelines [8]. The surgical team should be aware of the patient's peptide history so they can interpret any unexpected glucose excursions.

Step 5: Post-Operative Clearance Before Resuming

Do not restart AOD-9604 until the following conditions are met: the surgical wound is in active primary healing (typically day 10 to 14 post-op), oral intake has returned to baseline, and the primary surgeon provides written or documented verbal clearance. HealthRX requires a brief telemedicine check-in before the prescription is reactivated.

AOD-9604 Clinical Update: Where the Evidence Stands in 2025

The Metabolic Pharmaceuticals Phase II Trials

Between 2001 and 2004, Metabolic Pharmaceuticals ran a series of Phase II trials examining oral AOD-9604 for obesity. The most frequently cited result is a modest but statistically significant reduction in body weight versus placebo over 12 weeks [4]. The oral bioavailability of peptides is generally poor, and the injectable compounded form used in today's telehealth prescribing differs substantially from the oral formulations tested. Extrapolating Phase II oral efficacy data to injectable dosing carries significant uncertainty.

Regulatory Status in 2025

AOD-9604 is not FDA-approved as a drug. The FDA removed it from the list of bulk substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act in 2015 [11]. However, enforcement discretion and state pharmacy board interpretations have varied, and some 503A compounding pharmacies continue to dispense it. Prescribers should verify their state's current compounding regulations before prescribing.

The FDA's Office of Pharmaceutical Quality guidance on bulk drug substances states that a compound may not be used in 503A compounding if it has been withdrawn from the market for safety reasons or if it appears on the FDA's negative list [11]. Patients and prescribers should check the current FDA bulk substances list at accessdata.fda.gov before initiating or continuing therapy.

Mechanistic Research Since 2001

The Heffernan et al. Foundational paper established that AOD-9604 stimulates lipolysis in fat cells without activating the GH receptor and without raising IGF-1 in animal models [1]. A follow-up study by the same group examined the peptide's interaction with the beta-3 adrenergic receptor pathway using receptor-specific antagonists, supporting the conclusion that the mechanism is distinct from classical GH signaling [1].

Research published in Molecular and Cellular Endocrinology examined the role of the C-terminal GH fragment on adipocyte differentiation, finding that AOD-9604 inhibited lipogenesis in pre-adipocytes at concentrations of 10 to 100 nM in vitro [12]. These mechanistic insights help explain why the peptide may affect intra-operative lipid metabolism even when plasma levels are undetectable.

A 2019 review in Peptides assessed GH-derived fragments as potential metabolic therapeutics, noting that the absence of IGF-1 elevation distinguishes AOD-9604 from full-length GH and reduces the theoretical risk of insulin resistance associated with GH excess [13]. The same review flagged the lack of long-term human safety data as the principal barrier to broader clinical adoption [13].

What We Still Do Not Know

The following questions remain unanswered by peer-reviewed evidence as of mid-2025:

• Does subcutaneous AOD-9604 produce measurable changes in fasting FFA levels in humans at standard telehealth doses (250 to 500 mcg/day)?
• Does a 7-day washout fully normalize lipolytic enzyme activity in human adipose tissue?
• Are there clinically significant pharmacodynamic interactions between AOD-9604 and volatile anesthetics such as sevoflurane or desflurane?
• What is the impact of AOD-9604 on post-operative wound healing in humans?

Until these questions are answered with controlled human data, conservative hold protocols remain the standard of care at HealthRX.

Special Populations and Modified Hold Durations

Patients With Diabetes or Insulin Resistance

Patients using AOD-9604 alongside insulin, GLP-1 receptor agonists (semaglutide, tirzepatide), or SGLT-2 inhibitors require coordination across all agents before surgery. The ADA recommends holding SGLT-2 inhibitors at least 3 to 4 days before surgery due to risk of euglycemic ketoacidosis [8]. A parallel hold of AOD-9604 should begin at the same time, giving a minimum 7-day washout from the peptide independent of the SGLT-2 inhibitor timeline.

Patients on GH-Axis Peptides (Sermorelin, Ipamorelin, CJC-1295)

Many HealthRX patients use AOD-9604 alongside GHRH analogues or GHRP compounds. Each GH-axis peptide should be held separately, using the most conservative hold window that applies to any single agent in the stack. For sermorelin, published guidance from academic endocrinology centers recommends a minimum 5- to 7-day hold before elective procedures [14]. The combined stack therefore requires the full 7-day hold, starting from the most recent dose of any agent in the combination.

Patients Scheduled for Bariatric Surgery

Bariatric procedures involve significant peri-operative metabolic management. Endocrine Society Clinical Practice Guidelines on obesity pharmacotherapy recommend stopping all weight-loss adjuncts, including peptides and GLP-1 agonists, at least 2 weeks before bariatric surgery [15]. For AOD-9604 in this setting, HealthRX uses a 14-day pre-operative hold to align with bariatric protocol.

Patients Over Age 65

Older adults metabolize peptides more slowly due to reduced renal clearance and decreased hepatic enzymatic activity. Although no AOD-9604-specific PK data exist for this population, general peptide pharmacokinetic principles from studies of other GH-axis fragments suggest a 20 to 30 percent longer effective half-life in patients over 65 [16]. The 7-day hold remains adequate given the large safety margin, but the prescriber should document the age-related consideration in the clinical note.

Communicating the Hold to Your Surgical Team

Surgeons and anesthesiologists are less familiar with compounded peptides than with branded pharmaceuticals. Clear communication prevents errors.

What to Tell Your Anesthesiologist

Bring a printed or digital record that includes the peptide name (AOD-9604, HGH fragment 176-191), the dose in micrograms, the route (subcutaneous injection), the frequency, and the exact date of the last dose. The American Society of Anesthesiologists recommends that patients disclose all supplements, biologics, and compounded agents at least 7 days before surgery [3]. The anesthesiologist may not recognize "AOD-9604" by name but will understand "a subcutaneous lipolytic peptide that acts on beta-3 adrenergic receptors and was last administered 8 days ago."

Documentation in the Medical Record

The prescribing provider at HealthRX should include a hold note in the patient's chart that states the specific hold start date, the surgical procedure planned, and the conditions required for resumption. This documentation protects both the patient and the prescriber if any peri-operative complication occurs.

If Surgery Is Urgent or Emergent

Planned holds are irrelevant in a true emergency. If a patient on AOD-9604 requires emergent surgery, the anesthesia team should be informed of the peptide use but should not delay a life-saving procedure for washout. In animal studies, AOD-9604 showed no cardiovascular toxicity at doses up to 1,000 mcg/kg [1]. The peri-operative team can manage metabolic variables as they arise.

Resuming AOD-9604 After Surgery

The 14-Day Post-Op Minimum

HealthRX requires a minimum 14-day post-operative interval before restarting AOD-9604. This window allows initial wound healing to proceed under normal endogenous hormonal conditions. Fibroblast proliferation, collagen cross-linking, and angiogenesis during the first two weeks of healing are sensitive to hormonal environment [17].

Post-Op Lab Requirements Before Resuming

Before the prescriber reactivates the AOD-9604 prescription, the patient should provide:

• Fasting glucose (target <100 mg/dL or at pre-operative baseline)
• C-reactive protein (CRP) below 5 mg/L, indicating resolution of acute surgical inflammation
• Surgeon clearance note in the chart

Restarting at a Lower Dose

After a surgical hold of 14 days or more, HealthRX recommends restarting AOD-9604 at 50 percent of the pre-operative dose for the first 2 weeks. This mirrors standard re-titration principles used for GLP-1 agonists after surgical holds, where the Endocrine Society recommends dose reduction on restart to avoid GI or metabolic side effects [15]. At week 3, the patient may return to the full maintenance dose if labs and symptoms are stable.